A comprehensive approach to the molecular determinants of lifespan using a Boolean model of geroconversion by Verlingue, Loic et al.
A comprehensive approach to the molecular
determinants of lifespan using a Boolean model of
geroconversion
Loic Verlingue, Aure´lien Dugourd, Gautier Stoll, Emmanuel Barillot,
Laurence Calzone, Arturo London˜o-Vallejo
To cite this version:
Loic Verlingue, Aure´lien Dugourd, Gautier Stoll, Emmanuel Barillot, Laurence Calzone, et al..
A comprehensive approach to the molecular determinants of lifespan using a Boolean model of
geroconversion. Aging Cell, Wiley Open Access, 2016, <10.1111/acel.12504>. <hal-01366791>
HAL Id: hal-01366791
http://hal.upmc.fr/hal-01366791
Submitted on 15 Sep 2016
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Distributed under a Creative Commons Attribution 4.0 International License
A comprehensive approach to the molecular determinants of
lifespan using a Boolean model of geroconversion
Loic Verlingue,1,2 Aure´lien Dugourd,3 Gautier Stoll,4,5,6
Emmanuel Barillot,3 Laurence Calzone3,† and
Arturo London˜o-Vallejo1,7,†
1Institut Curie, CNRS, UMR3244, Telomere and Cancer Laboratory, PSL
Research University, 75005 Paris, France
2Department of Medical Oncology, Institut Curie, 75005 Paris, France
3Institut Curie, Mines Paris Tech, Inserm, U900, PSL Research University,
F-75005 Paris, France
4Sorbonne Paris Cite, Universite Paris Descartes, 12 Rue de l’Ecole de
Medecine, 75006 Paris, France
5Equipe 11 labellisee Ligue contre le Cancer, INSERM U 1138, Centre de
Recherche des Cordeliers, 15 rue de l’Ecole de Medecine, 75006 Paris, France
6Universite Pierre et Marie Curie, 4 Place Jussieu, 75005 Paris, France
7UPMC Univ Paris 06, CNRS, UMR3244, Sorbonne Universites, 75005 Paris,
France
Summary
Altered molecular responses to insulin and growth factors (GF)
are responsible for late-life shortening diseases such as type-2
diabetes mellitus (T2DM) and cancers. We have built a network of
the signaling pathways that control S-phase entry and a specific
type of senescence called geroconversion. We have translated
this network into a Boolean model to study possible cell
phenotype outcomes under diverse molecular signaling condi-
tions. In the context of insulin resistance, the model was able to
reproduce the variations of the senescence level observed in
tissues related to T2DM’s main morbidity and mortality. Further-
more, by calibrating the pharmacodynamics of mTOR inhibitors,
we have been able to reproduce the dose-dependent effect of
rapamycin on liver degeneration and lifespan expansion in wild-
type and HER2–neu mice. Using the model, we have finally
performed an in silico prospective screen of the risk–benefit ratio
of rapamycin dosage for healthy lifespan expansion strategies.
We present here a comprehensive prognostic and predictive
systems biology tool for human aging.
Key words: Boolean modeling; lifespan expansion; in silico
drug screening; rapamycin; type 2 diabetes mellitus; cancer.
Introduction
New translational tools are required to implement our increasing
understanding of the molecular determinants of age-related diseases
into clinical interventions (Fontana et al., 2014). Aging is an organismal
phenomenon associated with the progressive accumulation of senescent
cells in tissues. This is a consequence of both an increase in pro-
senescence signals and an impairment in the senescent cells’ clearance
(Lopez-Otın et al., 2013). Cell senescence, which corresponds to a
permanent growth arrest, is thought to negatively impact tissue function
and thus to drive the manifestation of age-related diseases (Mu~noz-Espın
& Serrano, 2014). Persistent telomeric or genomic damages, oncogene
activation, epigenomic perturbations, and/or tumor suppressor inactiva-
tion are among the main triggers of cell senescence (Campisi, 2013).
However, an integrative approach to validate the molecular mechanisms
that control S-phase entry and transient/permanent cell growth arrest
remains elusive (Piano & Titorenko, 2015). Furthermore, measuring the
impact of the cell senescence on disease outcome represents a major
clinical challenge.
The pharmaceutical inhibition of mTOR (comprising mTORC1 and/or
mTORC2) is the most reproducible intervention to expand lifespan in
preclinical models and correlates with a reduction of cell senescence
proportions in many species including humans (Harrison et al., 2009;
Anisimov et al., 2010; Popovich et al., 2014; Warner, 2015). Still, the
pro-proliferative activity of mTORC1 is conceptually difficult to reconcile
with its role in permanent growth arrest. Moreover, a prophylactic mTOR
inhibition may inevitably expose individuals to well-known treatment’s
toxicities (MacDonald & RAPAMUNE Global Study Group, 2001; Mahe
et al., 2005; Ferte et al., 2011). Modeling the dose-related benefits and
risks of rapamycin treatment in the molecular network that controls
senescence could therefore contribute to healthy lifespan expansion
strategies for humans.
Geroconversion is a specific type of cell senescence resulting from the
inappropriate activation of growth signals in nonproliferative cells. At the
molecular level, several studies have reported that the co-activation of
mTORC1 and CDKN1A (p21) is necessary to trigger geroconversion
(Astle et al., 2012; Hasty et al., 2013; Blagosklonny, 2014). While AKT is
both responsible for the activation of mTORC1 and the inhibition of
CDKN1A’s nuclear functions, questions persist about how mTORC1 and
CDKN1A activations can occur concomitantly (Zhou et al., 2001). We
have hypothesized that the numerous regulatory feedback loops in the
PI3K/AKT/mTOR pathway may be responsible for the decoupling of
mTORC1 and CDKN1A activities from AKT regulation thus allowing
geroconversion to occur.
To test this hypothesis, we have first built a network of the
molecular mechanisms involved in geroconversion and S-phase entry.
Then, by translating it into a Boolean model, we have been able to
precisely reproduce the level of cell senescence in tissues from humans
and mice with type-2 diabetes mellitus (T2DM) compared to normal.
Next, we have simulated the effect of rapamycin on lifespan expansion
reported in the three largest longevity studies in mice for different
genetic background and rapamycin doses. Prompted by the coherence
of our results with experimental published data, we have finally
proposed a prospective screen of the effect of rapamycin on lifespan
expansion, balanced with the toxicity of rapamycin on oral mucosa.
With this study, we aim at providing a comprehensive view of the
molecular network of geroconversion to help defining precise thera-
peutic strategies.
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Results
Construction of the mathematical model
After selecting the key genes participating in the pathways we wished to
describe, we gathered known facts about the regulations of these genes
from the literature (Table S1, Supporting information). The network that
recapitulates this information is of the form of an influence network
where nodes are genes, complexes, or processes, and edges are positive
or negative influences. To build the molecular network that regulates
geroconversion, we have started with the well-documented regulations
between the PI3K/AKT/mTOR and the p53/CDKN1A pathways (Hasty
et al., 2013). We have added a simplified network of the cell cycling
regulatory system to obtain a coherent behavior of the S-phase entry
readout (Aguda & Algar, 2003). We have then enriched the network
with influences described in the literature about the constitutive
regulations of the PI3K/AKT/mTOR pathway (Table S1). We have
deliberately limited our model to these pathways to specifically analyze
the impact of the metabolism signaling on cell cycling and senescence.
By analyzing the resulting network, we have identified numerous
feedback loops that represent constitutive regulations (Appendix S1,
Supporting information). We have also identified a context-specific
circuit. Indeed, it has been described that excessive glucose uptake and
obesity result in both insulin pathway-dependent and pathway-
independent mTORC1 and S6K1 activity (Laplante & Sabatini, 2012).
The persistent activity of S6K1 (mTORC1_S6K1 in the model) is known to
negatively regulate the upstream insulin receptor substrate 1 (noted
IRS1_PIK3CA in the model; Laplante & Sabatini, 2012). This inhibitory
influence is suspected to be the cause of insulin resistance that defines
type-2 diabetes mellitus (T2DM; Laplante & Sabatini, 2012). We have
therefore split the model into a normal model without this feedback and
a T2DM model encompassing it (Fig. 1). The network was then
translated into a Boolean model by adding logical rules to each of the
variables of the two versions of the model and was simulated
stochastically (see Materials and methods). One of the main advantages
of Boolean models is that there are almost no parameters to tune. To
simulate the model stochastically, we set all the initial conditions as
random. The time-dependent probabilities of the nodes’ activities were
obtained using MaBoSS (Stoll et al., 2012), by setting the initial
probability of the nodes’ activities to 0.5. Some of the variables
represent ‘phenotypes’: They integrate the activity of several nodes and
they can be understood as readouts of the model. When the model is
perturbed, these probabilities change and it is this particular change that
is studied, compared to experimental data, and interpreted qualitatively.
T2DM increases geroconversion
To assess the explanatory power of our model, we have initially
evaluated how the influence responsible for the T2DM model could
reproduce biological observations. As previously mentioned, the initial
states of each variable of the model have been set with a probability of
activity of 0.5 to fully cover all possible conditions. Concerning the inputs
of the model (growth factors – GF, and insulin), we have observed that
the predictions fit better the biology when the insulin node is
permanently activated and the GF node is random. Importantly, this is
consistent with the high blood concentrations of insulin during the day in
humans (Daly et al., 1998). The main effect of the T2DM-specific
influence can be summarized as follows: In the normal model,
IRS_PIK3CA is only regulated by insulin (IRS_PIK3CA active 100% of
the time, same as insulin; Fig. 2, left panel). However, in the T2DM
model, the IRS_PIK3CA activity depends on both insulin and
mTORC1_S6K1 and thus is less active under the same insulin input,
validating the driving effect of this functional feedback on insulin
resistance (IRS_PIK3CA active 33% of the time for 100% constant
insulin activity; Fig. 2, right panel). The consequence of a weaker activity
of IRS_PIK3CA in response to high insulin level is a reduction of AKT
activity, and as a consequence, a much stronger activation of CDKN1A.
Meanwhile, mTORC1_S6K1 activity is partially conserved, creating a
favorable situation for mTORC1_S6K1 and CDKN1A to trigger gerocon-
version. Indeed, there is a fourfold increase of the mean probabilities of
senescence in the T2DM model compared to the normal model (Fig. 2).
The activity of the senescence output obtained from the model was
then compared to the proportions of cell senescence reported in the
literature for normal and diabetic humans and mice. The method in
Fig. 1 The influence network of
geroconversion. The model has been built
from the literature. Inputs are growth
factors (GF) and insulin. Outputs are
senescence, S-phase entry (G1_S), and
metabolism. Red nodes are pro-proliferative
factors, green nodes are antiproliferative
factors, green arrows represent activations,
and red arrows represent inhibitions. The
thick edge concerning IRS_PIK3CA
inhibition by mTORC1_S6K1 defines the
type diabetes model. The normal model is
identical in everything but without this thick
edge. The gray node ‘Therapy’ represents
mTOR inhibitors. The exhaustive list of
literature references for the molecular
network of geroconversion is in
Appendix S1.
Modulating the molecular network of aging, L. Verlingue et al.2
ª 2016 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
study selection is described in the Appendix S2. Cell types such as
hepatocytes, endothelial cells, renal cells and adipocytes are highly
relevant for T2DM clinical complications in humans (Wang et al., 2009;
Minamino et al., 2009; Aravinthan et al., 2013; Liu et al., 2014; Yuan
et al., 2015). By simulating the model in the conditions reported below,
we observed that the probabilities of senescence calculated from the
simulations of the normal model perfectly coincide with the proportions
of cell senescence reported for nondiabetic humans and mice (Fig. 3A).
As for the diabetic model, the probabilities precisely reproduce the
difference in the cell senescence proportions for diabetic humans and
mice (Fig. 3A). With the model, we have computed the cell proliferation
kinetics from the probabilities of S-phase entry and corrected by the
probabilities of senescence (see Materials and methods for equation of
cell proliferation). For both the normal and diabetic models, the
simulations also efficiently reproduce the proliferation kinetics of
hepatocytes as evaluated by BrdU incorporation for normal and T2DM
mice (Fig. 3B), further reinforcing the validity of our results (Yang et al.,
2004).
The in silico simulations of this set of coherent biological observations
suggest that the network structure we propose for geroconversion can
be considered reliable. We have therefore frozen the model in its present
configuration and have performed prospective simulations. We have
searched the literature for comparable biological or clinical studies to
find relevant biological interpretations for our results. (Appendix S2). For
instance, our model predicts a 3.8 higher level of senescence in the
T2DMmodel, which approximates the 3 times faster whole brain volume
shrinkage detected in patients with diabetes. This result also approxi-
mates the 4.7-fold increase in beta-galactosidase-positive (i.e. senescent)
beta islet area found in mice with high-fat diet, but with lower basal
proportions (studies discussed in the Appendix S2). In all, increased
geroconversion in patients with T2DM could be proposed as a unifying
mechanism for T2DM-related tissue complications.
Bona fide predictions of the normal and T2DM models also suggest
an altered cell metabolism induced by T2DM. Cell metabolism is usually
defined by the utilization of nutrients for energy production in the
mitochondria, necessary for cell cycling and tissue function. In our
Normal
IRS_PIK3CAFig. 2 Simulations of the normal and the
diabetes models. mTORC1_S6K1, AKT,
senescence, and p21 are plotted using
MaBoSS: The percentages represent the
probability for a node of being active in
time (arbitrary scale). Initial states of every
variable simulated from the model are
defined as random (‘Other nodes?‘)
except for the insulin input defined=1
(‘Insulin? ‘). (Left panel) Simulations for
the normal model; (right panel) simulations
for the diabetes model.
Fig. 3 Comparison of the phenotypes
between the normal and diabetes models.
(A) The probabilities of senescence in the
normal and diabetes models (black dots)
reproduce the reported measurements of
cell senescence proportions in a variety of
tissues for the same conditions (color dots).
(B) The proliferation kinetics deduced from
the probabilities of S-phase entry (G1_S)
and senescence in the normal and diabetes
models (black and red lines) reproduce the
reported hepatocytes proliferation kinetics
for the same conditions.
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model, the variable ‘Metabolism’ corresponds to glycolysis, glycogenesis,
and protein synthesis and indirectly controls ATP production, cell cycling,
and FOXO activity (Table S1). Defective metabolism observed in T2DM
effectively drives muscle loss (sarcopenia) and impacts functional
capacities in the elderly (Leenders et al., 2013). Compared to the
normal model, the simulation of the T2DM model induces a 21%
reduction in metabolism (72% and 51% metabolism for the normal and
T2DM models, respectively). This rate is strikingly close to the 21–28%
skeletal muscle loss observed in T2DM mice, compared to normal (Wang
et al., 2006). While a similar tendency has been observed in humans,
raw data for metabolism change are not accessible for comparisons
(Leenders et al., 2013; Larsen et al., 2015).
How can T2DM induce both senescence and cancer?
Patients with diabetes have a significant increase in cancer incidence and
cancer-related mortality (Tsilidis et al., 2015). Nevertheless, it may
appear paradoxical that T2DM increases senescence, a well-known
tumor suppressive program for the cell, decreases cell metabolism, and
concomitantly increases tumor cell proliferation. It has been postulated
that peripheral insulin resistance induces a compensatory hypersecretion
of insulin by the pancreas. Indeed, the largest epidemiological studies on
this subject have identified hyperinsulinemia (or circulating C-peptide or
proinsulin) as a specific prognostic factor for cancer-related mortality
(Ma et al., 2008; Wolpin et al., 2009; Perseghin et al., 2012; Walraven
et al., 2013). We have therefore simulated the normal and T2DM
models as previously described, but with increasing levels of insulin (for
each simulation, initial condition for insulin set to 0, 0.5 and 1) as the
unique changing parameter. For each simulation, we have estimated
the proliferation kinetics by calculating the doubling time (dT) from the
probability of S-phase entry (G1_S) corrected by the probability that the
cells enter senescence (see Materials and methods). We have observed
that in the normal model, increasing levels of insulin proportionally
promote cell proliferation (Fig. 4, in red in the upper panels). The ratios
of dT under hyperinsulinemia (insulin level = 1) compared to the 0.5 or 0
insulin levels are 1.56 and 2.39, respectively (dTinsulin_1/dTinsulin_0.5 =
67.6/43.3 = 1.56; and dTinsulin_1/dTinsulin_0 = 67.6/28.2 = 2.39). This is
very close to the hazard ratios for cancer-related mortality concerning
patients with hyperinsulinemia, ranging between 1.62 and 2.38 (see
Materials and methods for details; Walraven et al., 2013; Perseghin
et al., 2012; Wolpin et al., 2009; Ma et al., 2008). Concerning the
T2DM model, insulin level barely modifies the calculated dTs (Fig. 4,
lower panels). These de novo predictions shed a new light on the
complex relation between T2DM, loss of tissue function, and cancers
(detailed in Appendix S3). Our Boolean model is in agreement with the
observations of T2DM-induced senescence and the prognostic value of
hyperinsulinemia in cancer. It could thus be used as a predictive tool for
pharmacological targeting.
Reproduction of the pharmacodynamics and the liver effect
of mTOR inhibitors
To account for a therapeutic intervention, we have introduced in the
model a new variable that inhibits mTORC1_S6K1 (variable ‘Therapy’ in
Fig. 1), without any other change in the model or parameters. A single
administration of an mTOR inhibitor has been simulated in the model by
an initial peak of activity followed by a smooth decrease of the variable
‘Therapy’, consistent with classical pharmacokinetics in mammals. The
simulated slope for a single 5 mg administration of everolimus has been
manually calibrated to fit the level of S6K1 inhibition at 168 hours
measured in the peripheral blood mononuclear cells (PBMC; Boulay
et al., 2004; Tanaka et al., 2008). By modifying the slope of decrease
(rate down) of the variable ‘Therapy’, it was possible to change its
inhibition of mTORC1_S6K1 (the syntax and the mathematical formulae
used to tune the parameters of the variable ‘Therapy’ can be found in
Materials and methods). Therefore, the effect of the 6 other treatment
doses and control in PBMC of humans and/or mice have been
prospectively simulated by modifying the slope of the variable ‘Therapy’
proportionally to the dose modification (Table S2 and Fig. S1, Supporting
information). The resulting probabilities of the inhibition of
mTORC1_S6K1 activity replicate the effect of everolimus on the
inhibition of S6K1 activity in humans and mice, validating this method-
ology to reproduce different doses of treatment (Pearson correla-
tion = 0.987, P value = 3.36e-05 for PBMC; Fig. 5A). It is also possible
to simulate a gain or loss of function in the model. For pancreatic
tumors, we have prospectively simulated the model with a p53 loss of
function and MAPK gain of function (the most frequent alterations of
pancreatic tumors) under the same doses of mTOR inhibitors. Again, we
have observed an accurate reproduction of the pharmacodynamics of
everolimus (Pearson correlation = 0.926, P value = 0.00271 for tumors).
Interestingly, the saturating effect of high doses of everolimus reported
by the authors has also been observed in our simulations: Above 30 mg,
the delta of mTORC1_S6K1 inhibition is blunted (Fig. 5A).
Periodic administrations of the same dose of the drug have been
simulated by a plateau of activity of the variable ‘Therapy’ estimated
from the residual activity at 24 h, which is consistent with classical
pharmacokinetics in mammals. At the tissue level, Wilkinson and
Fig. 4 Proliferation kinetics deduced from the probabilities of S-phase entry
(G1_S) and senescence in the normal models under an increasing initial activity of
the Insulin node. The probabilities of S-phase entry (G1_S) are represented by a red
bar and the probability of senescence by a gray bar. The ratios of the doubling
times (dTs, see below) in the normal model reproduce the cancer-related mortality
increase for hyperinsulinemia (dTinsulin_1/dTinsulin_0.5 = 67.6/43.3 = 1.56; and
dTinsulin_1/dTinsulin_0 = 67.6/28.2 = 2.39) The proliferation kinetics are deduced
from the probabilities of S-phase entry (G1_S) and senescence by the calculation of
the dT with the formula: dT = log(2)/(G1_S - G1_S*Senescence). The formula for
the curves is f(x) = exp(G1_S *x- G1_S*Senescence*x).
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colleagues have analyzed the effect of a daily administration of
rapamycin on age-related liver degeneration, which corresponds to
NAFLD (Wilkinson et al., 2012). Because the pharmacokinetics of
everolimus and rapamycin are similar, the variable ‘Therapy’ calibrated
on a single 5 mg administration of everolimus has been used to calculate
the pharmacodynamics of oral rapamycin at different doses (Materials
and methods). We have deduced the probabilities of senescence from
the three doses of rapamycin and the control (Table S3 and Fig. S2).
Remarkably, the senescence probabilities highly correlate with the
reported proportion of liver degeneration (Pearson correlation = 0.997,
P value = 0.00271; Fig. 5B). Together with the previous observations,
these data support that geroconversion of the cell is causal in NAFLD and
can be efficiently prevented by rapamycin treatment in a dose-
dependent manner.
Predicting lifespan expansion: the in silico contribution to
rapamycin dosage
The effect of rapamycin on lifespan expansion is the most reproducible
intervention for many species including mice, the latter being assessed in
large ‘longevity studies’. Reasons for the selection of these studies are
provided in the Appendix S3. The genetic background of the mice,
rapamycin dose, schedules, and administration route of the three largest
longevity studies fitted for comparison had been precisely reproduced in
our simulations (Materials and methods; Harrison et al., 2009; Anisimov
et al., 2010; Popovich et al., 2014). We have hypothesized that the
probabilities of senescence from the model could approximate the
probability of mortality in mice cohorts. Therefore, the probabilities of
senescence for each simulation have been plotted by a negative, linear
function of time, from 100% to 0% (Figs S3 and S4; Table S4). The
differences between the senescence proportions in the ‘treatment’ and
‘no treatment’ groups at 90%, and for one study at 50%, mortality,
have been compared to the corresponding data reported in the three
longevity studies. The in silico quantifications of lifespan increase with
rapamycin coincide with the ratios of mice survival (Fig. 5C). This result
supports the high predictive value of the therapeutic simulations of the
Boolean model and warrants its use to perform an in silico screen of the
effect of rapamycin on lifespan expansion.
As the model efficiently predicts the senescence probabilities in
humans and mice (Fig. 3A), we aimed at specifying the modalities for
human prophylactic rapamycin treatment. From this perspective, it
appears important to concomitantly consider the drug’s toxicity. Oral
ulcer is the best-studied and most frequent dose-related adverse event of
mTOR inhibitors. It is one of the earliest ones, and perhaps the one that
degrades the most the quality of life of treated patients. We have
therefore pooled together the data about the dose-dependent oral
ulcers incidence reported in three human studies for everolimus and
rapamycin (MacDonald AS & RAPAMUNE Global Study Group, 2001;
Mahe et al., 2005; Ferte et al., 2011). We have found a linear relation
between the published doses of mTOR inhibitors (in log scale) and oral
ulcers appearance (Fig. S5). From this relation, 100% oral ulcers occur
for 0.21 mg kg1 day1 of everolimus or rapamycin (Fig. S6). Interest-
ingly, we have observed that the estimated doubling time from our
model fits the oral ulcer appearance from the literature in a dose-related
manner (Pearson correlation = 0.942; Fig. S6A and B). Furthermore, the
physiological doubling time of gastrointestinal mucosa and hematopoi-
etic cells, 48 h, is fitted by our model (Odorico et al., 2001; Fowler et al.,
2003; Yang et al., 2011, p.4). These observations underlie the great
ranges of possibilities the model offers for therapeutic management of
mTOR inhibitors.
We have therefore performed a screen of the doses of rapamycin
between 0 and 0.21 mg kg1 day1 to predict the lifespan increase
from the model. The lifespan increase with rapamycin has been deduced
from the difference with the control group at mean 90% mortality. The
estimations from the model have identified a 6.8% lifespan expansion
for a dose corresponding to 100% incidence of oral ulcers of all grades
(Fig. 6). Interestingly, the risk–benefit ratio varies with the dose. For
0.06 mg kg1 day1, we predict with the model a 5.4% survival
0.5
5
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A B C
Fig. 5 Simulations of the pharmacodynamics of mTOR inhibitors: predicted vs. published results. (A) For everolimus, simulated increasing levels of mTOR inhibition are
proportional to the doses reported in (Boulay et al., 2004 ; Tanaka et al., 2008). The probabilities of mTORC1_S6K1 activities to the pharmacodynamics of everolimus in
PBMC (peripheral blood mononuclear cells, Table S2; corresponding to the normal model) are compared to the pancreatic tumors (corresponding to the normal model with
p53 loss of activity and MAPK gain of activity). Pearson correlation = 0.987, P value = 3.36e-05 for PBMC and Pearson correlation = 0.926, P value = 0.00271 for tumors.
(B) For rapamycin, simulated increasing levels of mTOR inhibition are proportional to the doses reported in (Wilkinson et al., 2012). Probabilities of senescence from the
normal model are plotted with respect to the liver degeneration (corresponding to NAFLD) in male mice (Table S3): Pearson correlation = 0.997, P value = 0.00271. (C)
Reproduction of the lifespan increase under rapamycin from 3 longevity studies. Longevity study #1: Simulation of intravenous administration of rapamycin at 2.24 mg
kg1day1 for genetically heterogeneous female mice. Longevity study #2: Simulation of subcutaneous administration of rapamycin at 1.5 mg kg1 3 times a week for
2 weeks followed by a 2-week break for HER2–neu mice. Longevity study #3: Simulation of subcutaneous administration of rapamycin at 0.45 mg kg1, 3 times a week for
2 weeks followed by a 2-week break for HER2–neu mice (Table S4 and Figs 3 and 4).
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increase with 55% oral ulcers appearance, which corresponds to a gain
of 4 years in a population with 80-year-old lifespan expectancy. A dose
of 0.03 mg kg1 day1 rapamycin still provides an interesting 4.2%
predicted lifespan expansion while provoking less oral ulcer appearance
(30%). These results could help refining the dose of mTOR inhibitors for
future clinical trials.
It is still debated whether rapamycin expands lifespan per se or if it
reduces age-related diseases such as T2DM or cancers. In HER2–neu
mice, Anisimov and colleagues have shown a reduction in cancer
incidence for mice treated with rapamycin (Anisimov et al., 2010). With
the model, the percentage reduction in cell proliferation between the
control and the rapamycin model with MAPK hyperactivation reproduces
this difference: 33.7% reduction of tumor-bearing mice in the literature
vs. 32% in the model (Fig. S7). This result brings insight in the coexisting
roles of mTORC1 inhibition in both lifespan expansion per se and cancer
prevention.
Discussion
According to the World Health Organization, type-2 diabetes mellitus
currently concerns 347 million people worldwide, which is projected to
increase to more than 550 million and to represent the 7th leading cause
of death by 2030 (http://www.cdc.gov/diabetes/home/index.htlm;http://
www.who.int/en/). This highlights the need for precocious prevention
strategies. With a generic model of geroconversion, we have been able
to precisely reproduce the increase in cell senescence related to the
greatest morbidity and mortality for patients with T2DM: cardiovascular
complications, nephropathy, and NAFLD (Fig. S8). Consistently, our
model correlates to the reported faster whole brain volume shrinkage
and metabolism defects in patients with T2DM, while providing
molecular scenarios to explain the higher incidence of tissue-specific
cancers in that population. Our model also efficiently reproduces the
hazard ratios reported for cancer-related mortality in patients with
hyperinsulinemia. The correct in silico results of such diverse phys-
iopathological behaviors reported across multiple large biological and
clinical studies allow us to conclude that the molecular network we have
built does reflect one of the essential biological processes of the cell cycle
control in mammals, and should be used as a basis to explore further
hypotheses.
The importance of cell senescence triggered by mTORC1 activity has
been recently highlighted from the rapamycin studies. The studies we
used for the parameterization of the model about T2DM induced
senescence focused on cases where the effect of the classical causes of
senescence was minimized, namely persistent telomeric or genomic
damages, oncogene activation, epigenomic perturbations, and/or tumor
suppressor inactivation. Several topic-related studies were excluded from
our work for infeasible comparison (Appendix S2 and S3). We identified
two studies that have reported a lower senescence proportions in the
normal and T2DM conditions than in the other transorgan studies,
however conserving a similar difference induced by T2DM compared to
our model. Unfortunately, the authors do not address this inadequacy in
their publications; therefore, we have not used them in Fig. 3A.
Concerning the epidemiological studies on cancer prognosis and the
longevity studies on mice, we aimed at being exhaustive, as long as the
studies were comparable to our simulations with a reliable statistical
power (Appendix S3). More comparisons and experimental reproduc-
tions would have reinforced the predictive power of our model.
However, we decided to concentrate on a selected number of studies
that had very large-scale and high-quality reported data.
Mathematical modeling of molecular networks is still an emerging
field that aims at verifying and testing biological and pharmacological
hypotheses. We provide in this study a new methodology to simulate the
pharmacodynamics of everolimus and rapamycin. Using this methodol-
ogy, we have calibrated the activity of the variable ‘Therapy’ on a single
5 mg administration of everolimus and have deduced all the other
dosages. We have define that cell senescence modulation under
treatment could constitute a reliable surrogate marker of tissue function
and lifespan. It has allowed us to reproduce the effect of these drugs on
mice liver degeneration and lifespan with an unprecedented accuracy
compared, to our knowledge, to the largest and most reliable longevity
studies to date.
In the field of mathematical modeling, Boolean models rely on coarse-
grain descriptions rather than precise details of biochemical reactions
involved in the processes we describe. This formalism allows us to
minimize the number of parameters that need to be tuned, but this is
carried out at the expense of the type of predictions that can be made.
We coped with this issue by simulating the model with a modeling tool,
MaBoSS, which performs stochastic simulations of the Boolean model
and provides quantitative outputs by modulating a very limited amount
of parameters (only one parameter was tuned here). Other types of
formalisms, for example, chemical kinetics, could permit a more precise,
or more qualitative analysis, but the very little amount of information on
the reaction parameters compromises the realization of such mathe-
matical models.
The fact that such a relatively simple molecular network is able to
provide such a comprehensive and accurate view of very diverse
biological and clinical observations may be surprising. At the same time,
these observations support the view that our model is equilibrated and
covers a fundamental mechanism for cell cycle control in mammals.
Clearly, robust models must rely on strong experimental evidences used
to construct the network. It seems important to permanently verify the
coherence of the network during the construction phase, and to stick to
well characterized mechanisms. Given the complexity of the biology of
0.06
55%
5.4%
4.2%
30%
0.03
mg kg–1 d–1)
Fig. 6 Predicted effect of rapamycin on survival and oral ulcer from the model.
Simulated screen of rapamycin doses up to 0.20 mg kg1 day1 to quantify the
survival increase at 90% mean mortality. The dose-related oral ulcer appearance
has been deduced from published data (Figs S5 and S6). Two doses are
represented with their risk–benefit ratio (dashed gray and black line).
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molecular interactions, the model has to maintain an equilibrium and
therefore could suffer from too many details in particular modules thus
impacting the whole network. Larger models shall express exponential
complexity to keep on fitting the biology. Nevertheless, this first model
of geroconversion together with our new methodology to simulate
therapies may contribute to the understanding and management of
major health problems related to aging, namely T2DM and cancers.
Materials and methods
Experimental design
Molecular interactions are necessary for signal transduction in the cell.
We have manually curated the molecular signals in response to growth
factors and insulin activation, from the literature (Table S1). The network
obtained has been translated into a mathematical model using a logical
formalism to calculate the probabilities of S-phase entry and senescence.
Thereby, the molecular conditions of published studies have been
reproduced in the model to compare the in silico predictions to the
biological phenotypes.
Boolean modeling
Boolean logic, a discrete dynamical formalism, is based on a low-
resolution description of a molecular network. Nodes represent entities
such as genes, proteins, complexes, and processes, and edges represent
their mutual influences. Each node can be found in 2 states: 1 (on) or 0
(off). The activating or repressing influences on a target node are defined
by the logical gates: AND, OR, NOT. Nodes can also be transiently or
permanently forced into a Boolean state, which is used to simulate the
effect of extracellular signals, or genomic alterations, for example.
Various simulation strategies can be applied for Boolean models. First,
we have computed the attractors of the Boolean model to define the
stable states or limit cycles using GINsim (Naldi et al., 2009). Then, we
have simulated the model stochastically to assess the probabilities of the
phenotypes ‘senescence’ or ‘G1_S’ and of some internal variables of the
model. These calculations were performed using MaBoSS software,
which allows the stochastic simulations of Boolean models (Stoll et al.,
2012). It computes the probabilities of activation of each node over
continuous time by simulating a Markov process using the Gillespie
algorithm. The model is freely available at the BioModels database
(https://www.ebi.ac.uk/biomodels-main/) and GINsim (http://ginsim.org)
repositories. MaBoSS script is also provided in this article (Appendix S4).
T2DM data
Biological data that evaluate the impact of T2DM on tissues were
retrieved from the literature with a particular attention on the most
frequent T2DM tissue-specific complications in the clinic (for the
selection’s rational see Appendix S2). Selected studies that have
measured the senescence proportions in humans and mice have focused
on hepatocytes from 70 patients, progenitor endothelial cells from 83
patients, differentiated endothelial cells frommice, proximal tubular renal
cells from 30 patients, and adipose cells from mice, corresponding to the
following T2DM clinical complications: NAFLD, cardiovascular complica-
tions, diabetic nephropathy, global inflammation, and aggravation of
insulin resistance, respectively (Wang et al., 2006, 2009;Minamino et al.,
2009; Aravinthan et al., 2013; Liu et al., 2014; Yuan et al., 2015). One of
the studies also evaluates the BrdU incorporation in time of cells from
obese and nonobese mice obtained by hepatic biopsy (Yang et al., 2004).
Hyperinsulinemia and cancers’ mortality
Four large epidemiological studies have evaluated the relation
between hyperinsulinemia (or surrogate markers like circulating C-
peptide or proinsulin) and cancer-related mortality. For unselected
cancer types, high levels of circulating proinsulin or insulin are
associated with hazard ratios of 2.01 and 1.62 for mortality in 438
and 2011 individuals, respectively (Perseghin et al., 2012; Walraven
et al., 2013). For colorectal and prostate cancers, high levels of
circulating C-peptide are associated with hazard ratios of 1.87 and
2.38 for mortality in 373 and 2546 patients, respectively (Ma et al.,
2008; Wolpin et al., 2009).
Simulations protocol
To be compared with the biological data, the simulations have been
performed assuming the following rules:
1 Every stochastic simulation has been pursued until a stable state of
probabilities is reached, except when a specific time is necessary, for
example for the therapy calibration.
2 Every node in the model has been simulated with a probability of
initial activity of 0.5, except for the simulations of hyperinsulinemia
(Insulin initial state = 1) and mTORC1 inhibition (Therapy initial
state = 1).
3 The parameters ruling the interactions between the nodes (rate up
and rate down) have been equally set = 1, and no rates have been
fitted except for, and limited to 1) the variable therapy (rate used to
simulate doses, described thereafter) and 2) the simulation of the
p53 loss of function and the MAPK gain of function (MaBoSS script
available in Appendix S4).
4 The curves of BrdU incorporation and cell proliferation kinetics have
been arbitrary calculated by the exponential function of the
probability of S-phase entry (G1_S) corrected by the probability
that the cells undergo senescence:
5 f(t) = exp(G1_S*t - G1_S*Senescence*t)
6 The estimations of the doubling time (dT) from the simulations have
been arbitrary calculated with the formula: dT= log(2)/(G1_S -
G1_S*Senescence)
The experimental procedures of the three longevity studies have been
reproduced in the simulations for the estimations of lifespan and
carcinogenesis (Harrison et al., 2009; Anisimov et al., 2010; Popovich
et al., 2014). The estimation of lifespan has been performed using the
probabilities of senescence as a linear decreasing function in time, by:
f(t) = 1-Senescence*t.
Therapeutic simulations protocol
An input node ‘Therapy’ that inhibits mTORC1_S6K1 has been added
to the initial model and used to simulate the effect of everolimus and/
or rapamycin (Fig. 1). The corresponding syntax in MaBoSS is as
follows:
Node Therapy {
rate_up = $u_ Therapy;
rate_down = $d_ Therapy;
}
Node mTORC1_S6K1 {
logic = (!AMPK & !TSC);
rate_up = (@logic AND NOT Therapy) ? $u_mTORC1_S6K1: 0;
rate_down = @logic ? 0: $d_mTORC1_S6K1;
}
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where $u_ Therapy and $d_ Therapy are assigned to a numeric value
and correspond to the rate of increase ($u) or decrease ($d): These
parameters are tuned to match the experimental observations.
We first set the initial state of Therapy to 1 to simulate the initial peak
of treatment concentration. To calibrate the value of $u_ Therapy and
$d_ Therapy, we used data from (Boulay et al., 2004; Tanaka et al.,
2008). Authors have performed a single administration of several doses
of everolimus to humans and rats and have measured their effects on
S6K1 during 168 hours in PBMC (considered to be wild-type for the
simulations) and pancreatic tumors (considered to harbor a p53 loss of
function and a MAPK gain of function for the simulations). The
pharmacokinetics and pharmacodynamics reported for a single admin-
istration of 0.5 mg/kg everolimus have been considered as the reference
dosage. Therefore, the parameter for the slope of decrease of the
variable ‘Therapy’ was tuned to obtain 19% of S6K1 inhibition at
168 hours ($u_ Therapy = 0.035 and $d_ Therapy = 1-$u_ Therapy).
The transformation factors from 0.5 mg kg1 have been used to
calculate the slope of the simulated therapy for other doses (Table S2).
As the blood pharmacokinetics of rapamycin is similar to the blood
pharmacokinetics of everolimus for the same dose, the previous
reference dosage was used to simulate several doses of rapamycin
(http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scie
ntific_Discussion_-_Variation/human/000273/WC500046440.pdf). Sen-
escence probabilities from the simulations of daily administration of
rapamycin at 3 different doses were compared to the proportion of
age-related liver degeneration in mice (Wilkinson et al., 2012).
Furthermore, the effect of rapamycin on lifespan expansion in mice
reported in 3 ‘longevity studies’ was used for comparison. First, Harrison
and colleagues have evaluated the oral administration of rapamycin at
2.24 mg kg1 day1 in 1916 genetically heterogeneous mice and
matched controls and have found a 14% increase in survival at 90%
mean mortality for female mice (Harrison et al., 2009). Second,
Anisimov and colleagues have assessed the effect on lifespan and
carcinogenesis of subcutaneous administration of rapamycin at
1.5 mg kg1, 3 times a week for a period of 2 weeks followed by 2-
week intervals without rapamycin, on HER2–neu female mice. They have
found 4.1% and 11% lifespan increase at 50% and 90% mean
mortality, respectively (Anisimov et al., 2010). Third, Popovich and
colleagues have used the same transgenic HER2–neu mice model to
assess the effect on lifespan and carcinogenesis of rapamycin subcuta-
neous at lower doses, namely 0.45 mg kg1, 3 times a week for
2 weeks followed by a 2-week break (Popovich et al., 2014). They have
found a mean 3.3% increase in lifespan from their 3 treatment groups.
The subcutaneous administration has been simulated by a correction of
0.1 from the oral doses consistent with the known 10% bioavailability of
subcutaneous rapamycin (Crowe et al., 1999).
Statistics
The data analyses, statistic tests, and plots have been performed using
the R software version 3.1.2 (2014-10-31). The correlations have been
calculated with the Pearson test. Linear regressions and corresponding
p-values have been calculated with the function linear model (lm) of the
package ‘stats’.
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